Patients and injectors will, of course, make their own assessments of Daxxify’s duration of effect, regardless of how RVNC promotes the product. Still, as noted in #msg-170775983, I would prefer that RVNC use a soft sell, minimizing the likelihood of dissatisfied customers and injectors.
Daxxify is a great product that will “sell itself” in due course, so RVNC should take care to circumvent the overpromise/underdeliver pitfall.
Market Data 
Markets 
AI
